Home › Funds › Epoch Investment Partners, Inc. › REGN

Epoch Investment Partners, Inc. position in REGN

REGENERON PHARMACEUTICALS · Health Care

Epoch Investment Partners, Inc. reported holding 181,531 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$137.6M, representing 0.82% of its reported portfolio and ranking #32 among its reported holdings. Epoch Investment Partners, Inc. has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)181.53K sh
Reported value held$137.65M
Portfolio Weight0.82%
First reportedQ1 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Epoch Investment Partners, Inc.'s REGN position evolved

Epoch Investment Partners, Inc. first disclosed a stake in REGN in Q1 2024 at 103,551 shares (US$99.7M). The position peaked in Q4 2025 at 281,335 shares, worth US$217.2M. Across 11 filings, Epoch Investment Partners, Inc. increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 181,531 shares valued at US$137.6M — a reduction of -5,319 shares quarter over quarter.. Notable position changes include a 58% increase in Q2 2024 (shares were roughly flat over the following quarter), a 25% increase in Q4 2024 (shares fell 11% over the following quarter), a 28% increase in Q3 2025 (shares rose 36% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 103.55K $99.67M New
Q2 2024 163.30K $171.63M Add
Q3 2024 157.74K $165.82M Reduce
Q4 2024 197.27K $140.52M Add
Q1 2025 207.46K $131.57M Add
Q2 2025 203.06K $106.60M Reduce
Q3 2025 259.15K $145.71M Add
Q4 2025 281.33K $217.15M Add
Q1 2026 238.72K $184.45M Reduce
Q2 2026 186.85K $116.51M Reduce
Q3 2026 181.53K $137.65M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has Epoch Investment Partners, Inc. held REGN?

Epoch Investment Partners, Inc. has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is Epoch Investment Partners, Inc.'s current position in REGN?

As of Q3 2026, Epoch Investment Partners, Inc. holds 181.53K shares of REGN (REGENERON PHARMACEUTICALS), valued at $137.65M, representing 0.82% of its reported portfolio and ranking #32.

Has Epoch Investment Partners, Inc. been buying or selling REGN?

In the latest 13F filing (Q3 2026), Epoch Investment Partners, Inc. reduced its position in REGN. The position peaked in Q4 2025 at 281.33K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.